Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:05 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 439 matching trials from the live ClinicalTrials.gov search.

Filters: "biochemical recurrence" Clear all

Conditions: Prostate Cancer
Interventions: Radiation, Radical Prostatectomy; Radiation · Procedure
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 70 Years · Male only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 2
States / cities: Durham, North Carolina • Richmond, Virginia

Conditions: Breast Cancer, Colorectal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastric Cancer, Head and Neck Cancer, Liver Cancer, Lung Cancer, Metastatic Cancer, Ovarian Cancer, Pancreatic Cancer, Testicular Germ Cell Tumor
Interventions: CEA RNA-pulsed DC cancer vaccine; Biological
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2002
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Prostate Cancer
Interventions: Docetaxel, Androgen Hormonal Suppression and Radiation, Androgen Suppression Therapy and Radiation Therapy; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 30 Years and older · Male only
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Prostate Adenocarcinoma
Interventions: CT-guided Stereotactic Body Radiation Therapy, MRI-guided Stereotactic Body Radiation Therapy, Questionnaire Administration; Radiation · Other
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 179 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Prostate Cancer
Interventions: Disulfiram; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Male only
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 3
States / cities: Baltimore, Maryland • Durham, North Carolina • Philadelphia, Pennsylvania

Conditions: Hereditary Coproporphyria (HCP), Acute Intermittent Porphyria (AIP), Variegate Porphyria (VP)
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 15 Years and older
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 6
States / cities: Birmingham, Alabama • San Francisco, California • New York, New York + 3 more

Conditions: Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor, Ovarian Cancer, Teratoma, Testicular Germ Cell Tumor
Interventions: filgrastim, carboplatin, ifosfamide, paclitaxel, autologous hematopoietic stem cell transplantation, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Recurrent Prostate Carcinoma
Interventions: Best Practice, Computed Tomography, Gallium Ga 68-labeled PSMA-11, Positron Emission Tomography; Other · Procedure · Radiation
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: Male only
Enrollment: 193 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 2
States / cities: Los Angeles, California • San Francisco, California

Conditions: Prostate Cancer, Prostate Disease
Interventions: Nivolumab, Brachytherapy, External Beam Radiation Therapy, Androgen Deprivation Therapy; Drug · Radiation
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Diffuse Large B-cell Lymphoma
Interventions: RAD001, LBH589, Doublet (RAD001 and LBH589); Drug
Lead sponsor: Anne Beaven, MD; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Prostate Adenocarcinoma, Stage I Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7, Stage III Prostate Adenocarcinoma AJCC v7
Interventions: Hypofractionated Radiation Therapy, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Radiation Therapy; Radiation · Other
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older · Male only
Enrollment: 296 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 229
States / cities: Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 188 more

Conditions: Cervical Cancer, Uterine Cancer
Interventions: 18F fluciclovine, 18F fluciclovine PET; Drug · Device
Lead sponsor: Nghi Nguyen; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Prostate Cancer
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Male only
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Prostate Cancer
Interventions: Docetaxel, Prednisone; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: Male only
Enrollment: 298 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2016
U.S. locations: 33
States / cities: Birmingham, Alabama • Tucson, Arizona • North Little Rock, Arkansas + 30 more

Conditions: Prostate Cancer
Interventions: Satraplatin plus radiation therapy; Drug
Lead sponsor: Agennix; Industry
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 4
States / cities: San Francisco, California • Dallas, Texas • San Antonio, Texas + 1 more

Conditions: Metastatic Cancer, Prostate Cancer
Interventions: paricalcitol, immunoenzyme technique, laboratory biomarker analysis, dual x-ray absorptometry, quality-of-life assessment; Drug · Other · Procedure
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 120 Years · Male only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Prostate Cancer
Interventions: eVisit; Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 4
States / cities: Cary, North Carolina • Durham, North Carolina • Raleigh, North Carolina

Conditions: Ovarian Cancer, Genitourinary (GU) Tumors
Interventions: Epacadostat, tamoxifen; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 17
States / cities: La Jolla, California • Los Angeles, California • San Francisco, California + 14 more

Conditions: Calcinosis
Interventions: calcitonin; Drug
Lead sponsor: National Center for Research Resources (NCRR); NIH
Eligibility: 0 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1992
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Prostate Cancer
Interventions: Pasritamig; Drug
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Prostate Cancer
Interventions: Degarelix, Goserelin acetate; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 8
States / cities: Aurora, Colorado • Denver, Colorado • Dover, Delaware + 5 more

Conditions: Prostate Cancer, Malignant Neoplasm of Prostate, Secondary Malignant Neoplasm of Prostate
Interventions: Androgen deprivation therapy (ADT), Androgen receptor signaling inhibitor (ARSI), Local Therapy: Radical Prostatectomy (RP) or Radiotherapy (RT), Metastasis directed radiotherapy (MDRT); Drug · Other · Radiation
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 3
States / cities: New York, New York • Cleveland, Ohio • Madison, Wisconsin

Conditions: Prostate Cancer
Interventions: flotufolastat (18F), piflufolastat (18F); Drug
Lead sponsor: Blue Earth Diagnostics; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 9
States / cities: Phoenix, Arizona • Duarte, California • Los Angeles, California + 6 more

Conditions: Prostate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Interventions: Gonadotrophin Releasing Hormone, Intensity-Modulated Radiation Therapy, Niraparib; Biological · Radiation · Drug
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older · Male only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 94
States / cities: Gilbert, Arizona • Tucson, Arizona • Duarte, California + 77 more

Search by objective public record fields.

Preoperative Radiation Therapy for High Risk Prostate Cancer

Biological Therapy in Treating Patients With Metastatic Cancer

Hormone Suppression and Radiation Therapy for 6 Months With/Without Docetaxel for High Risk Prostate Cancer

CT-guided Stereotactic Body Radiation Therapy and MRI-guided Stereotactic Body Radiation Therapy for Prostate Cancer, MIRAGE Study

Study of Recurrent Prostate Cancer With Rising Prostate Specific Antigen (PSA)

Clinical Diagnosis of Acute Porphyria

Paclitaxel, Ifosfamide, and Carboplatin Followed By Autologous Stem Cell Transplant in Treating Patients With Germ Cell Tumors That Did Not Respond to Cisplatin

Multicenter Randomized Trial of 68Ga-PSMA-11 PET/CT Based SRT After Radical Prostatectomy

Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy

Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer

Pilot Study to Assess the Potential Clinical Utility of 18F Fluciclovine PET for Cervical and Endometrial Cancer.

Evaluation of Neuroendocrine Differentiation as a Potential Mechanism of Tumor Recurrence Following Radiotherapy

Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma

A Phase I Trial of Satraplatin Plus Radiation Therapy for Prostate Cancer Patients With Biochemical Recurrence

Paricalcitol in Treating Patients With Advanced Prostate Cancer and Bone Metastases

Electronic Post-Treatment Surveillance Program for Prostate Cancer Survivors (eHealth)

A Phase 2 Study of the IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy

Phase II Study of Calcitonin for Tumoral Calcinosis

Testing Pasritamig Before Surgery for the Treatment of Localized Prostate Cancer

A Degarelix Trial in Patients With Prostate Cancer

MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)

Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men With Low PSA Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy

Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring